Related Experiment Video
Updated: Oct 26, 2025
An Educational Video Demonstration of How to Prone a Critically Ill Intubated Patient
Published on: November 30, 2022
COVID-19, corticosteroids and public health: a reappraisal
1Medbase, 114 Milton Avenue, Chapel Hill, NC, 27514, USA.
Insights
Dexamethasone is beneficial for hospitalized COVID-19 patients needing respiratory support. Wider use in outpatients or preventatively may increase mortality and mucormycosis, necessitating clearer public health guidance.
Area of Science:
- Infectious Diseases
- Pharmacology
- Public Health
Background:
- Regulatory guidance exists for dexamethasone use in hospitalized COVID-19 patients.
- A surge in global dexamethasone demand suggests its use may extend beyond recommended indications.
- The current guidance may not adequately emphasize risks associated with broader application.
Purpose of the Study:
- To evaluate the applicability of current dexamethasone guidance for COVID-19 to the broader patient population.
- To investigate potential adverse outcomes linked to off-label dexamethasone use.
- To recommend clarifications for public health guidelines regarding dexamethasone.
Main Methods:
- Analysis of data from the RECOVERY trial and WHO prospective meta-analysis.
- Literature review using PubMed with keywords: COVID-19, RECOVERY trial, WHO meta-analysis, variants, immunity, public health.
- Deconstruction and analysis of existing trial and meta-analysis data.
Main Results:
- WHO guidance on corticosteroids for COVID-19 is primarily based on the RECOVERY trial data within a prospective meta-analysis.
- Dexamethasone demonstrates efficacy specifically in hospitalized COVID-19 patients requiring respiratory support.
- Increased global demand indicates potential widespread use in outpatients and for prophylaxis.
Conclusions:
- Dexamethasone's therapeutic value for COVID-19 is confined to a specific group: hospitalized patients needing respiratory support.
- Extensive use beyond these indications may contribute to increased mortality and the emergence of mucormycosis.
- Public health recommendations for dexamethasone in COVID-19 require clarification and a cautionary statement regarding risks.
Objectives:
To assess whether regulatory guidance on the use of dexamethasone in hospitalised COVID-19 patients is applicable to the larger population of COVID-19 cases. The surge in worldwide demand for dexamethasone suggests that the guidance, although correct, has not emphasised the danger of its wider use.
Study Design:
Data from the Randomised Evaluation of COVID-19 Therapy (RECOVERY) trial and the World Health Organisation (WHO) prospective meta-analysis have been deconstructed and analysed.
Methods:
To provide context, relevant publications were identified in PubMed using the following keywords: COVID-19, RECOVERY trial, WHO meta-analysis, variants, immunity, public health.
Results:
The WHO guidance 'Corticosteroids for COVID-19' was based on their prospective meta-analysis. This meta-analysis was weighted by data from the RECOVERY trial.
Conclusions:
In terms of COVID-19, dexamethasone has value in a narrow indication, namely, in hospitalised patients requiring respiratory support. The media blitz likely resulted in the wider use of dexamethasone in outpatients and as a preventive medication. This is reflected in the surge in worldwide demand for dexamethasone. We ask whether the use of steroids, beyond regulatory indications, may be responsible for the recent increase in mortality and especially the emergence of mucormycosis? From the public health standpoint, the current guidance for use of dexamethasone in COVID-19 could benefit from clarification and the addition of a cautionary note.
Related Concept Videos
01:26COPD: Management Using Bronchodilators and Corticosteroids
01:25Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
01:17Drugs Used in Lower Respiratory Disorders: Overview
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
01:14Myocarditis III: Medical Management
01:20Asthma: Pathogenesis and Management
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
01:17Pericarditis III: Medical Management